Skip to main content

Table 2 Secondary outcome results

From: Effects of mind-body interventions on polycystic ovary syndrome: a comprehensive meta-analysis

Outcome categories

Outcome

No. of studies

MD (95%CI)

Heterogeneity

(I2, %)

Anthropometrics

Weight (kg)

3

0.05 (-0.99, 1.09)

3.1

BMI

7

-0.24 (-0.51, 0.03)

0

waist circumference (cm)

2

-0.46 (-1.44, 0.53)

0

hip circumference (cm)

3

-0.61 (-3.41, 2.19)

43.01

waist-hip ratio*

4

-0.02 (-0.03, -0.01)

0

Endocrine parameters

mFG score

4

-0.78 (-1.61, 0.06)

68.40

FSH (mIU/mL)

2

-0.23 (-1.27,0.80)

0

LH

2

-2.68 (-11.56, 6.21)

86.66

LH/FSH ratio

2

-0.69 (-2.21, 0.83)

66.68

SHBG (nmol/L)

2

8.87 (-4.99, 22.73)

0

DHEAS((µg/dL)

2

-16.98 (-51.52, 17.56)

89.58

Total testosterone(mmol/L)

4

-2.11 (-4.41, 0.18)

91.75

Free testosterone(pg/mL)

2

-0.94 (-2.30, 0.42)

78.26

glucose metabolism and blood lipid marker

Fasting insulin(µU/ml)

3

-2.88 (-6.31, 0.56)

24.56

Fasting blood glucose (mmol/L) *

3

-0.25 (-0.36, -0.14)

0

HOMA-IR*

4

-0.69(-1.22, -0.15)

0

triglycerides(mmol/L) *

4

-0.21 (-0.41, -0.01)

51.96

HDL (mmol/L)

4

-0.02 (-0.09, 0.05)

0

LDL (mmol/L)

4

0.04 (-0.27, 0.35)

70.90

Total cholesterol(mmol/L)

3

0.05 (-0.27, 0.37)

13.26

  1. * means The differences were statistically significant (P < 0.05). BMI: Body Mass Index; mFG score: Modified Ferriman-Gallwey score; FSH: Follicle-Stimulating Hormone; LH: Luteinizing Hormone; SHBG: Sex Hormone-Binding Globulin; DHEAS: Dehydroepiandrosterone sulfate; HOMA-IR: Homeostatic Model Assessment of Insulin Resistance; HDL: High-density lipoprotein; LDL: Low-density lipoprotein